On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.
Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.
The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.
On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.
Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.
it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.
Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.
It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.
It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.
Credit: AI image
Pennsylvania has reported its eighth measles-associated death of 2026 as the US battles a major outbreak that cost it its measles elimination status.
The news came a day after the Pan American Health Organization (PAHO) announced that the US, Mexico, and Bolivia had lost their measles elimination status. The US had maintained their measles-free status since 2000.
Pennsylvania has recorded around 1,589 confirmed cases across 46 counties, prompting authorities to urge people to check their vaccination status and ensure they are adequately protected. The total number of cases in the US has crossed more than 5,700.
The latest death, confirmed on November 18, involved an unvaccinated resident of Clinton County who had tested positive for measles. Health authorities have not disclosed the individual's age or other relevant details. According to the Pennsylvania Department of Health, the state has also reported 315 hospitalisations linked to the outbreak.
With measles cases spreading everyday, questions about whether adults who received measles vaccines during childhood need another dose have emerged. Health experts believe that most people who have received the recommended two doses of the measles, mumps and rubella (MMR) vaccine do not need a booster.
According to the US Centers for Disease Control and Prevention (CDC), adults born in 1957 or later who do not have evidence of immunity should receive at least one dose of the MMR vaccine. But certain groups are recommended to receive two doses, separated by at least 28 days. These include:
People who have received two documented doses of the MMR vaccine, with the first administered at or after 12 months of age and the doses appropriately spaced, are considered protected for life.
Also read: Not Just US, Mexico & Bolivia Also Lose Measles-Free Status: RFK Jr & CDC Chief Respond
According to the CDC, adults born before 1957 are presumed to have immunity against measles because the virus circulated widely before the vaccine became available in 1963.
However, healthcare workers born before 1957 who do not have a history of previous measles infection should consider receiving two doses of the MMR vaccine.
People vaccinated between 1963 and 1967 with the older inactivated (killed) measles vaccine may also need another dose. This version was later found to be ineffective.
The MMR vaccine is a live attenuated vaccine, which means it contains weakened forms of the viruses.
Pregnant women and people with severe immune suppression should generally not receive it. Individuals with a history of severe allergic reactions to a previous dose or vaccine component should also seek medical advice.
People who are unsure about their vaccination history, immune status or need for another dose should consult their healthcare provider.
Measles is one of the most contagious infectious diseases. The virus spreads through respiratory droplets and airborne particles. They can remain active in the air for up to two hours after an infected person leaves an area.
Symptoms typically start with fever, cough, runny nose and red, watery eyes, followed by a rash that usually starts on the face and spreads across the body.
Complications can include pneumonia, brain inflammation (encephalitis), permanent disability and death. Infants, young children and people with weakened immune systems are vulnerable. The resurgence has been attributed to declining vaccination coverage.
Credit: iStock
The US Centers for Disease Control and Prevention (CDC) has reported elevated activity of multiple respiratory viruses across the country during the 2026–27 winter season, including rhinovirus/enterovirus and respiratory adenovirus.
While respiratory adenovirus infections are increasing in some regions, the agency says the trends are expected.
In its latest update, the CDC also highlighted Group A strep infections, whooping cough and Mycoplasma pneumoniae, the bacteria responsible for walking pneumonia, as other respiratory illnesses circulating in the US.
Rhinovirus/enterovirus and respiratory adenovirus activity are elevated nationally, according to the CDC. Respiratory adenovirus infections are also increasing in some parts of the country.
Both viruses can cause respiratory symptoms such as cough, fever, nasal congestion and shortness of breath. In severe cases, infections may progress to bronchitis or pneumonia.
Rhinoviruses are among the common causes of the common cold and can also trigger asthma attacks. People with asthma, weakened immune systems or other underlying medical conditions may be at higher risk of severe illness.
Respiratory adenoviruses typically cause mild cold- or flu-like symptoms but can also lead to bronchitis, pneumonia, conjunctivitis (pink eye) and gastrointestinal illness. People with weakened immune systems or existing respiratory or cardiac conditions are at greater risk of severe disease. There are no vaccines available to the public for these infections.
Reports of Group A strep infections increased in the US as children returned to school this fall, before stabilising, the CDC said.
Most reported infections have involved strep throat or scarlet fever.
However, the bacteria can also cause serious conditions, including streptococcal toxic shock syndrome and necrotising fasciitis, commonly known as flesh-eating disease.
Although most infections are minor, serious illness can occur, particularly among older adults and people with certain underlying health conditions. Healthcare providers can diagnose the infection through testing and prescribe antibiotics when needed.
Respiratory infections caused by Mycoplasma pneumoniae remain low in most parts of the US, based on emergency department visits and positive test results.
The bacteria commonly cause tracheobronchitis, often described as chest colds, but can also lead to walking pneumonia. People of all ages can get infected, although school-aged children and young adults are most commonly affected.
Most mild infections resolve without medication, while healthcare providers may prescribe antibiotics for pneumonia.
Whooping cough, or pertussis, continues to circulate at lower levels compared with post-pandemic peaks, according to the CDC.
The highly contagious respiratory infection is caused by the bacterium Bordetella pertussis and can spread easily from person to person.
Babies younger than one year are at the highest risk of severe disease and complications. Vaccination is the best way to prevent complications, and healthcare providers generally treat the infection with antibiotics.
The CDC recommends basic precautions to reduce the spread of respiratory viruses and bacteria, including:
Credit: iStock
An estimated 370,000 people developed rifampicin-resistant tuberculosis (RR-TB) worldwide in 2025, highlighting the continuing threat of drug-resistant TB, according to the World Health Organization (WHO).
The Global Tuberculosis Report 2026 showed a gradual decline in RR-TB since 2015. However, major gaps in diagnosis and treatment persist.
Only 155,333 people were diagnosed with RR-TB and started treatment in 2025, just 42% of the estimated number who developed the disease.
Drug-resistant TB occurs when bacteria become resistant to one or more medicines. Rifampicin resistance is particularly concerning because rifampicin is a key first-line TB drug.
Also read: Global TB Deaths Fall 35% Since 2015, But 2030 Target Remains Distant: WHO
The proportion of new TB cases involving rifampicin resistance fell from 4.4% in 2015 to 3.1% in 2025.
Resistance remained higher among previously treated patients: 14.8% had RR-TB in 2025, down from 20% in 2015.
China, India, the Philippines and the Russian Federation together accounted for more than half of estimated global RR-TB cases in 2025.
Eastern Europe and Central Asia reported the highest proportions of RR-TB among previously treated patients, exceeding 50%.
India was also among five countries — alongside China, Indonesia, Pakistan and the Philippines — that accounted for about 60% of the global gap between estimated RR-TB cases and people enrolled on treatment.
Rifampicin-resistant TB is listed in WHO's Bacterial Priority Pathogens List under the critical group.
WHO identifies two main drivers of multidrug- and rifampicin-resistant TB (MDR/RR-TB): inappropriate treatment and person-to-person transmission.
Incorrect use of TB medicines, poor-quality formulations, improper storage and premature treatment stoppage can contribute to drug resistance.
Resistant bacteria can also spread between people. Those with pulmonary TB can transmit the infection through coughing, sneezing or talking. Others become infected by inhaling airborne bacteria.
Timely diagnosis, appropriate treatment and infection prevention are particularly important in crowded settings such as hospitals and prisons.
Read More: 15 Lakh Asymptomatic TB Cases Detected In India: How TB Mukt Bharat Abhiyaan Is Driving Screening
The treatment success rate for RR-TB reached 70% among patients who started treatment in 2023, the latest year with available outcome data.
This was below the 71% recorded in 2022 but above the rates in 2021 (68%), 2020 (64%) and 2012 (50%).
By comparison, treatment success for drug-susceptible TB is about 90%, according to WHO.
Across WHO regions, RR-TB treatment success ranged from 56% in the Region of the Americas to 77% in the African Region.
WHO recommends all-oral regimens for drug-resistant TB, including shorter courses for eligible patients. Six-month regimens accounted for 42% of RR-TB treatment in 2025, up from 18% in 2024 and 3% in 2023.
By the end of 2025, 106 countries were using these regimens, compared with 98 in 2024 and 60 in 2023.
They were the most frequently used treatment option in five of the six WHO regions. Uptake was highest in the Eastern Mediterranean (72%) and African (65%) regions.
Europe was the only region where longer regimens remained the main option for a large share of patients (76%).
WHO recommends the six-month BPaLM regimen — bedaquiline, pretomanid, linezolid and moxifloxacin — for eligible patients with MDR/RR-TB.
Treatment choices depend on drug resistance, previous exposure to TB medicines and other clinical factors.
Expanding access to rapid drug-resistance testing, starting treatment promptly and preventing transmission remain key to tackling drug-resistant TB.
© $2026 Times Horizon Private Limited